Logo

GATC Biotech's GATCLiquid

Sep 11, 2015

GATC Biotech has released a new liquid biopsy offering for early-access clinical research and product development called GATCLiquid Technology Suite. Based on next-gen sequencing and GATC's proprietary analysis techniques, the suite is aimed at the detection of genomic alterations in circulating DNA for diagnostic purposes, such as identifying clinically actionable genomic alterations that influence tumor development or treatment outcomes.

GATC says it has already sequenced more than 40,000 samples from blood and plasma, the majority under diagnostic conditions.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.